Duke Health contracts with most major health insurance carriers and transplant networks, including the ones listed below. Before scheduling your appointment, we strongly recommend you contact your insurance company to verify that the Duke Health location or provider you plan to visit is included in your network. Your insurance company will also be able to inform you of any co-payments, co–insurances, or deductibles that will be your responsibility. If you proceed in scheduling an appointment and your health insurance benefits do not participate with Duke, your out of pocket liability may be higher. We will contact you regarding your coverage and patient liability. If you are uninsured, learn more about our financial assistance policy.
Andrew J. Muir, MD, MHS
I am proud to serve as the Chief of the Duke Division of Gastroenterology. In addition to my administrative duties, I enjoy my clinical practice focused on the care of patients with liver diseases. I also continue to participate in clinical research and hope that these studies offer our patients the latest advances and treatment options.
Clinical Focus and Research
We take part in studies of new therapies for patients with liver disease. Through our clinical trials, we can offer patients other treatment options and often earlier access to new therapies. It has been my privilege to take part in many of the studies of new drugs for hepatitis C over the last decade. These treatments are now available in our clinical practice, and we are very comfortable with these new drugs, given our experience in these clinical trials over the last several years. With the progress in hepatitis C, we are now turning our attention to other liver diseases. I have personally started to focus on primary sclerosing cholangitis and cirrhosis.
View Andrew Muir's publications on PubMed
- First Health
- Gateway Health Alliance
- Halifax Physician-Hospital Organization
- MultiPlan / Private Healthcare Systems
- OneNet PPO
Industry Relationships and Collaborations
This faculty member (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.
- Arbutus Biopharma
- Gilead Sciences, Inc.
- NGM Biopharmaceuticals
- Precision Bioscience
- ProQR Therapeutics
- Shionogi Pharma
- Shire Pharmaceuticals
- Taiwan J Pharmaceuticals